Publicaciones en las que colabora con ANTONIO ESPINOSA UBEDA (75)

2011

  1. Homodimeric bis-quaternary heterocyclic ammonium salts as potent acetyl- and butyrylcholinesterase inhibitors: A systematic investigation of the influence of linker and cationic heads over affinity and selectivity

    Journal of Medicinal Chemistry, Vol. 54, Núm. 8, pp. 2627-2645

2009

  1. Acyclonucleosides, modified seco-nucleosides, and salicyl- or catechol-derived acyclic 5-fluorouracil O,N-acetals: Antiproliferative activities, cellular differentiation and apoptosis

    Current Medicinal Chemistry, Vol. 16, Núm. 9, pp. 1166-1183

  2. Homochiral drugs: A demanding tendency of the pharmaceutical industry

    Current Medicinal Chemistry, Vol. 16, Núm. 16, pp. 2064-2074

2008

  1. Anticancer activity of (1,2,3,5-tetrahydro-4,1-benzoxazepine-3-yl)-pyrimidines and -purines against the MCF-7 cell line: Preliminary cDNA microarray studies

    Bioorganic and Medicinal Chemistry Letters, Vol. 18, Núm. 4, pp. 1457-1460

  2. Design, synthesis and anticancer activity against the MCF-7 cell line of benzo-fused 1,4-dihetero seven- and six-membered tethered pyrimidines and purines

    Current Medicinal Chemistry, Vol. 15, Núm. 25, pp. 2614-2631

  3. From 5-fluorouracil acyclonucleosides to benzo-fused six- and seven-membered rings linked to pyrimidine and purine bases: The shift from differentiating anticancer agents to apoptotic inducers

    Expert Opinion on Drug Discovery, Vol. 3, Núm. 10, pp. 1223-1235

  4. Latest advances on regiospecif ic microwave-assisted synthesis of novel purine derivatives as antitumor agents

    Expert Opinion on Therapeutic Patents, Vol. 18, Núm. 2, pp. 211-222

  5. Regiospecific microwave-assisted synthesis and cytotoxic activity against human breast cancer cells of (RS)-6-substituted-7- or 9-(2,3-dihydro-5H-1,4-benzodioxepin-3-yl)-7H- or -9H-purines

    European Journal of Medicinal Chemistry, Vol. 43, Núm. 8, pp. 1742-1748

  6. Synthesis and anticancer activity of (R,S)-9-(2,3-dihydro-1,4-benzoxathiin- 3-ylmethyl)-9H-purines

    ChemMedChem, Vol. 3, Núm. 1, pp. 127-135

  7. Thermal N-9′ ← N-7′ isomerization of (6′- substituted)-9-(2,3-dihydro-5H-1,4-benzodioxepin-3-yl)-9H-purines in solution: Mechanistic aspects

    Mini-Reviews in Organic Chemistry, Vol. 5, Núm. 2, pp. 128-133

2007

  1. 1H and 13C NMR studies of 2-functionalized 5-(methylsulfonyl)-1-phenyl-1H-indoles

    Magnetic Resonance in Chemistry, Vol. 45, Núm. 2, pp. 185-188

  2. 5-fluorouracil derivatives induce differentiation mediated by tubulin and HLA class I modulation

    Medicinal Chemistry, Vol. 3, Núm. 3, pp. 233-239

  3. 6′-Chloro-7- or 9-(2,3-dihydro-5H-4,1-benzoxathiepin-3-yl)-7H- or 9H-purines and their corresponding sulfones as a new family of cytotoxic drugs

    Tetrahedron, Vol. 63, Núm. 1, pp. 183-190

  4. A synthetic uracil derivative with antitumor activity through decreasing cyclin D1 and Cdk1, and increasing p21 and p27 in MCF-7 cells

    Breast Cancer Research and Treatment, Vol. 105, Núm. 3, pp. 237-246

  5. Antiproliferative activity, cell-cycle dysregulation, and cellular differentiation: Salicyl- and catechol-derived acyclic 5-fluorouracil O,N-acetals against breast cancer cells

    ChemMedChem, Vol. 2, Núm. 12, pp. 1814-1821

  6. Corrigendum to "Synthesis and reactivity of (RS)-6-chloro-7- or 9-(1,2,3,5-tetrahydro-4,1-benzoxazepin-3-yl)-7H- or 9H-purines bearing a nitrobenzenesulfonyl group on the nitrogen atom". [Tetrahedron 63 (2007) 5274] (DOI:10.1016/j.tet.2007.03.155)

    Tetrahedron

  7. Cyclophanes and bicyclophanes: Fascinating molecules in organic chemistry

    Targets in Heterocyclic Systems, Vol. 11, pp. 431-448

  8. Design, syntheses, biological evaluation, and docking studies of 2-substituted 5-methylsulfonyl-1-phenyl-1H-indoles: Potent and selective in vitro cyclooxygenase-2 inhibitors

    ChemMedChem, Vol. 2, Núm. 1, pp. 88-100

  9. Erratum: (Current Medicinal Chemistry (2006) vol. 13 (2))

    Current Medicinal Chemistry

  10. QSAR as a tool for the development of potent antiproliferative agents by inhibition of choline kinase

    Current Computer-Aided Drug Design, Vol. 3, Núm. 4, pp. 297-313